glp-1 substance abuse Not just obesity: receptor agonists advance on addiction New Study Suggests GLP-1 Medications

In this work, we sought to determine if ALivE impacts future liver-related outcomes

The oral semaglutide offered through MadeMed is a compounded sublingual formulation - it is not the same product, does not use the same proprietary absorption technology, and has not been independently evaluated by the FDA for bioavailability, dosing equivalence, or absorption characteristics relative to the FDA-approved version

This review aims to consolidate available information from case reports and case series regarding rare skin-related adverse outcomes due to GLP-1 use, aiming to provide a comprehensive overview of the presentation, pathogenesis, and management for dermatologists and other clinicians

However, researchers acknowledge that the drugs efficiency could be hampered by its limited reach